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Abstract
Studies on familial aggregation of cancer may suggest an overall contribution of inherited genes or a shared environment in
the development of malignant disease. We performed a meta-analysis on familial clustering of prostate cancer. Out of 74
studies reporting data on familial aggregation of prostate cancer in unselected populations retrieved by a Pubmed search
and browsing references, 33 independent studies meeting the inclusion criteria were used in the analysis performed with
the random effects model. The pooled rate ratio (RR) for first-degree family history, i.e. affected father or brother, is 2.48
(95% confidence interval: 2.25–2.74). The incidence rate for men who have a brother who got prostate cancer increases 3.14
times (CI:2.37–4.15), and for those with affected father 2.35 times (CI:2.02–2.72). The pooled estimate of RR for two or more
affected first-degree family members relative to no history in father and in brother is 4.39 (CI:2.61–7.39). First-degree family
history appears to increase the incidence rate of prostate cancer more in men under 65 (RR:2.87, CI:2.21–3.74), than in men
aged 65 and older (RR:1.92, CI:1.49–2.47), p for interaction=0.002. The attributable fraction among those having an affected
first-degree relative equals to 59.7% (CI:55.6–63.5%) for men at all ages, 65.2% (CI:57.7–71.4%) for men younger than 65 and
47.9% (CI:37.1–56.8%) for men aged 65 or older. For those with a family history in 2 or more first-degree family members
77.2% (CI:65.4–85.0%) of prostate cancer incidence can be attributed to the familial clustering. Our combined estimates
show strong familial clustering and a significant effect-modification by age meaning that familial aggregation was
associated with earlier disease onset (before age 65).
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Introduction
Prostate cancer is one of the most common cancers among
males in developed countries [1]. A lot of evidence shows that a
family history of the disease is an important risk factor [1,2]. In
2003, three meta-analyses evaluated the increase in the risk of
prostate cancer in relatives of affected men [3–5]. Since then,
familial clustering has been assessed in a number of new
populations. Furthermore, more recent data is available from
the big cohorts in Sweden [6] and the US [7]. We studied all the
data available up to September 2010 to assess the strength of
prostate cancer familial aggregation. In order to evaluate the
impact of a family history of prostate cancer on the disease
incidence, we also estimated the attributable fractions among men
with affected relatives.
Methods
Searching
We browsed the PubMed database using the search term
‘(prostate cancer) and (family history)’. The last update was
performed September 21, 2010. Out of 801 initially identified
articles, 53 reports provided data on the relationship between
family history and risk of prostate cancer in an unselected
population of men (see Figure S1). Case-control studies using
selected populations as cases (example: patients undergoing
prostatectomy [8,9]) and cohort studies with a specific cohort
(example: smokers [10]) were excluded to avoid bias or
heterogeneity due to these population characteristics. Additional
21 study reports were found through the references of the studies
identified via the PubMed database.
Selection
74 relevant articles were coded. As quality control, we
considered study design, control for age and the way family
history was ascertained. Cohort studies and case-control studies
reporting age-adjusted estimates or using age-matched controls
were included. Cross-sectional studies [11–17] were excluded.
Two studies in which the attempt to match for age did not result in
a similar age of the cases and the controls [18,19] and one study in
which the controls were not age-matched and age-adjusted
estimates were not reported [20] were excluded. Additionally,
one case-control study was excluded [21], because none of the
participants reported a family history of prostate cancer. The study
of McCahy et al. [22] was not used in the main analysis, because it
was characterized by clearly outlying results (odds ratio for first-
degree family history 17.83). The influence of exclusion of this
study on the estimates was assessed in the sensitivity analysis.
Five studies [23–27] were excluded, because the investigated
type of familial clustering did not correspond to any of the
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analysis (affected first-degree relatives, i.e. father and/or brother(s),
versus not, affected father versus not, affected father versus no
affected first-degree relatives, affected brother(s) versus not,
affected brother(s) versus no affected first degree-relatives, affected
first or second-degree relative(s) versus not, two or more affected
first-degree relatives versus no history in first-degree relatives).
Two articles [28,29] were excluded because of the lack of
definition of ‘family history’.
Duplications in study populations were avoided so that each
pooled estimate was based on independent studies. In case of an
overlap between populations from several studies using the same
design, a case-control study with the largest number of participants
or the most recent cohort study was included. The case-control
study reported by Negri et al. [30] was preferred over Gallus et al.
[31] and Randi et al. [32], and Krain, 1974 [33] over Krain, 1973
[34]. Out of many reports based on the Swedish cancer register
[6,35–45], only the most recent [6] was used. Similarly, the most
recent findings were included from the studies using the Utah
population database [7,46,47] and the US Health Professionals
Cohort [48,49]. When there was a population overlap between
studies using a different design, the cohort study [6] was preferred
over the case-control studies [50–53], and the nested case-control
study [7] over the study of West et al. [54]. A summary of the 25
case-control studies [30,33,55–77] and 8 cohort-based studies
[6,7,49,78–82] included in the analysis is presented in Table 1 and
Table 2.
Data analysis
The combined estimates were expressed with the ratio of
incidence rates (RR) among those exposed and those not exposed.
The hazard ratios, the odds ratios from the logistic regression
models, and the odds ratios calculated from the contingency tables
were assumed to estimate the rate ratios. This measure of
association was considered appropriate to express the combined
estimates for several reasons. Firstly, the hazard ratios, which can
be estimated in cohort studies and density sampling case-control
studies [83], are valid estimates of the rate ratios [84]. Also the
odds ratios from the logistic regression models from density
sampling case-control studies can be used to estimate the rate
ratios without any adjustments [85]. Moreover, the bias
introduced by estimating the rate ratios with the odds ratios is in
Table 1. Summary of the case-control studies included in the analysis.
First author and
reference Date Place Race
Mean age at
diagnosis
No.
cases
No.
controls Controls
A
Beebe-Dimmer
55 1996–2002 USA: Michigan African 65 121 179 P C
Fincham
56 1981–1983 Canada: Alberta Caucasian NA, age 45 or older 382 625 P C M
Ghadirian
57 1989–1993 Canada: Montreal, Toronto, Vancouver Caucasian NA, median 70 640 639 P D M
Glover
58 1998
B Jamaica: Kingston African 73,3 263 263 H C M
Hayes
59 1986–1989 USA: Atlanta, Detroit, New Jersey Mixed 61,5
C 905 1264 P C M
Honda
60 1979–1982 USA: Los Angeles County Caucasian NA, 60 or younger 216 216 P C M
Justine
61 2001–2002 Australia: Perth Caucasian 63,8
C 560 450 P C M
Kolonel
62 1977–1983 USA: Hawaii Mixed NA 452 899 P C M
Krain
33 1971–1972 USA: Los Angeles Mixed median 69 210 215 H C M
Lesko
63 1992–1994 USA: Massachusetts Caucasian NA, median 65, age 70 or less 563 703 P D M
Magura
64 2004–2006 USA: North Dakota Caucasian 64,2
C 312 319 H C M
Mettlin
65 1995
B USA: Buffalo Caucasian 67,6 1271 1909 H C M
Negri
30 1991–2002 Italy Italian 65,7
C 1294 1451 H C
Rovito
66 1998–2001 USA: New York Caucasian 63,3
C 152 161 H C M
Rybicki
67 2001–2004 USA: Detroit Mixed NA, median 63 637 244 P C M
Salinas
68 1993–1996,
2002–2005
USA: King County, Washington Caucasian 59,9 1211 1208 P C M
Schuman
69 1977
B USA: Minnesota Caucasian NA, median 64 36 41 H D M
Spitz
70 1985–1989 USA: Texas Caucasian 66,2 378 383 H C M
Staples
71 1994–1998 Australia: Melbourne, Sydney, Perth Caucasian 60 1475 1405 P D M
Steele
72 1968–1969 Canada: Ontario Caucasian 69 39 39 H C M
Stone
73 1994–1995 USA: New Mexico Mixed 66,1 244 526 P C M
Strom
74 1998–2005 USA: Texas Hispanic 62,2 176 174 P C M
Suzuki
75 1988–2004 Japan Japanese NA 257 in total H C M
Whittemore
76 1987–1991 USA, Canada Mixed NA, mean age at interview: 71 1500 1581 P C M
Zhu
77 1989–1991 USA: Washington State Caucasian 64 175 258 P D M
AP–population based controls, H-hospital based controls, C–cumulative sampling, D–density sampling, M–age-matched controls.
BThe year of publishing. The period of collecting the data not reported.
CCalculated from the reported distribution of age of the cases at diagnosis.
NA–not available.
doi:10.1371/journal.pone.0027130.t001
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odds ratios [85].
When only raw data in a case-control study with age-matched
controls was available, the odds ratio and the confidence interval
were calculated from the contingency table. In case several
measures were available, the one adjusted for more variables was
preferred. If the results were reported in strata, the fixed effects
model was used to obtain the pooled estimate from the study.
Similarly to the previous meta-analyses on familial clustering of
prostate cancer [3–5], the estimates for men with affected father
relative to men without affected father were pooled with those
based on the reference category of men without family history in
first-degree family members. The same analysis strategy was
applied for men with affected brother(s). The estimates based on
the reference categories ‘men without affected brothers’ and ‘men
without affected first-degree relatives’ were pooled in one analysis.
In order to assess the public health implications of our findings,
we estimated the attributable fractions among those with a family
history of prostate cancer [86]. The measure was defined as the
proportion of the disease incidence attributable to the exposure.
The attributable fraction among those exposed can be expressed
as: AFE =( RR-1)/RR [84]. We estimated AFE by plugging in our
estimates of the rate ratios in the equation, which is often referred
to as the Mantel-Haenszel approach [87]. The confidence bounds
were obtained using the Wald method [88], with the standard
deviations estimated by the Monte Carlo simulation [89].
The estimates from the individual studies were combined on the
log scale. The Cochran’s Q statistic showed evidence of
heterogeneity greater than expected by the sampling variance
alone. Therefore, we used the random effects model to obtain the
combined estimates. For every combined estimate the funnel plot,
i.e. a plot of effects estimates versus their standard error, was
visually examined and the Egger’s asymmetry test [90] was used in
order to assess the presence of a publication bias. A meta-
regression was carried out to investigate the effect of study design
(cumulative sampling case-control versus other), ethnicity (Cauca-
sian versus other), country (US versus other) and publication year
on the rate ratio for first-degree family history. The effect of
ethnicity on the combined estimate was estimated using the mixed
effects model. To evaluate the effect of using the odds ratios from
the cumulative-sampling case-control studies as estimates of the
rate ratio, we also estimated the rate ratio for first-degree family
history using only the cumulative-sampling case-control studies
and compared it with the rate ratio based only on the density-
sampling case-control studies. Sensitivity of the findings was
examined by recalculation of the pooled association sizes after
exclusion of studies one by one. As all studies reporting familial
aggregation for men under 65 years old also provided data for the
age group 65 and older, the paired t-test was used to assess the
significance of the difference. The analysis was conducted in SAS
(version 9.2; Cary, NC, USA). The rmeta package of the R
software (version 2.11.1) was used for the plots.
Results
Pooled estimates
The pooled rate ratio for men with first-degree family history,
i.e. affected father or/and brother(s), was based on 19 case-control
[30,57–60,62–68,70–72,74–77], 3 nested case-control [7,80,82]
and 4 cohort studies [6,49,78,81]. 18 independent studies
[6,30,49,55–57,60,61,63–66,70,71,73,75,78,81] provided data for
men with history of prostate cancer in father and 16
[6,30,49,57,61,63–66,70,71,73,75,78,79,81] for men with history
of prostate cancer in a brother(s). The combined estimate for
history of prostate cancer in a second-degree relative was based on
5 studies [7,58,64,66,70]. Seven studies [6,57,62,63,66,71,76]
were used to estimate the rate ratio for 2 or more affected first-
degree family members. Five studies [6,49,63,65,71] provided data
for the different age groups.
The combined rate ratios and the corresponding attributable
fractions among those exposed are reported in Table 3. The rate
ratios for firstdegree family history, i.e. affected father or/and
brother(s) (Figure 1), affected father (Figure 2), and affected
brother(s) (Figure 3) were bigger than 2, with the confidence
level 95%. The estimated rate ratio for two or more affected
first-degree relatives equaled 4.39 (95% confidence interval:
Table 2. Summary of the cohort-based studies included in the analysis.
Author Date Place Race
Mean age at
diagnosis Design Cohort
Brandt
6 1961–2006 Sweden Caucasian NA, aged
younger than 75
Cohort study 3,900,000 men from the
Swedish cancer registry
Cerhan
78 1987–1995 USA, Iowa Caucasian 73,6
A Prospective
cohort study
1557 population-based controls from
case-control study in Iowa from 1987–1989
Chen
49 1990–2004 USA Caucasian NA Prospective
cohort study
B
43494 men from the Health
Professionals Follow-Up Study cohort
Kalish
79 1987–1997 USA, Boston area Caucasian 65,2
A Retrospective
cohort study
1149 men from the Massachusetts
Male Aging Cohort
Kerber
7 1966–2000 USA, Utah Caucasian NA Nested case-control,
density samping
11572 cases and 11572 controls
from the Utah Population Database
Park
80 1993–2006 USA, California Mixed NA Nested case-control,
cumulative sampling
729 cases and 729 controls
from the Multiethnic Cohort
Schuurman
81 1986–1992 The Netherlands Caucasian 64,2
A Prospective
cohort study
52879 men from the Municipal
population registries
Sun
82 1992–2006 USA Caucasian NA Nested case-control,
density sampling
1157 cases and 1157 controls from the Prostate
Lung and Ovarian Cancer Screening Trial cohort
ACalculated from the reported distribution of age of the cases at diagnosis.
BData on exposure to family history was available at baseline, however the updated data from 1996 was used in the analysis.
doi:10.1371/journal.pone.0027130.t002
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significantly higher for men younger than 65, than for men aged
65 or older, p=0.002.
59.7% of the incidence of prostate cancer in men with an
affected first-degree relative could be attributed to this risk factor
(CI: 55.6–63.5%). When two or more first-degree family members
were affected, the attributable fraction equaled 77.2% (CI: 65.4–
85.0%). For men younger than 65, the estimated attributable
fraction equaled 65.2% (CI: 57.7%–71.4%) and for men 65 or
older 47.9% (CI: 37.1–56.8%).
Publication bias and sensitivity analysis
The results of the Egger’s test for first-degree family history
(p=0.99), affected father (p=0.86), affected brother(s) (p=0.33),
and affected second-degree relative (p=0.06) did not indicate a
publication bias. The funnel plot for first-degree family history
suggests a potential publication bias (see Figure 4). In particular,
the rate ratio for the study by Suzuki et al. [75], a relatively small
study, is by far the largest from all the studies included in the
analysis. The sensitivity analysis showed that neither a decision to
include this study, nor any other shifted the estimate of the rate
ratio for first-degree family history or affected father more than by
0.1. Analysis conducted without the study by Chen et al. [49] gave
the rate ratio for affected brother(s) 0.18 bigger than the estimate
based on all the studies. Excluding none of the other studies led to
a change by more than 0.12.
The combined estimate for men aged 65 or older did not
change by more than 0.1, when one of the studies it was based on
was excluded. For the age category of men younger than 65, it
increased from 2.87 to 3.38 when the study by Chen et al. [49] was
not included, which was the largest change of the estimate when
one of the studies it was based on was excluded. The rest of the
estimates appeared to be more sensitive to changes in the sample
of studies. The studies by Magura et al. [64] and Kerber et al. [7]
had the largest effect on the estimate of the rate ratio for affected
second-degree family members. Excluding them changed the
estimate from 2.52 to 2.08 and 3.29 respectively. Not including the
study by Staples et al. [71] in the sample used to estimate the rate
ratio for two or more affected first-degree relatives led to a
decrease of the estimate from 4.39 to 3.89, and not using the study
by Lesko et al. [63] to an increase to 4.96, which were the largest
changes of the estimate when one of the studies it was based on
was excluded. Including the study by McCahy et al. [22] would
not change any of the combined estimates by more than 0.1.
The meta-regressions showed that neither the study design,
country, nor year of publication had a significant influence on the
combined estimates for first-degree relatives (p=0.40 for study
design, p=0.08 for country, and p=0.29 for publication year).
The estimated multiplicative effect of ethnicity on the rate ratio
equaled 1.04 (CI:0.83–1.30). The estimated rate ratio equaled 2.50
for Caucasian populations and 2.41 for other populations. This
difference was not significant, p=.75. The estimated rate ratio
based only on the cumulative-sampling case-control studies and
only on the density-sampling case control studies equaled 2.61
(CI:2.25–3.02) and 2.44 (CI:2.08–2.87) respectively.
Discussion
We identified 74 articles reporting information on the
association between family history and prostate cancer from
Table 3. Estimates of the rate ratios and the attributable
fractions among men with different types of family history.
Type of clustering RR (95% CI) AFE (95% CI) N
1st degree relatives
For all men 2.48 (2.25–2.74) 59.7% (55.6–63.5%) 26
For men before the age of 65 2.87 (2.21–3.74) 65.2% (57.7–71.4%) 5
For men aged 65 or older 1.92 (1.49–2.47) 47.9% (37.1–56.8%) 5
Affected father 2.35 (2.02–2.72) 57.4% (50.7–63.1%) 18
Affected brother(s) 3.14 (2.37–4.15) 68.1% (58.1–75.7%) 16
2+ 1st degree relatives 4.39 (2.61–7.39) 77.2% (65.4–85.0%) 7
2nd degree relatives 2.52 (0.99–6.46) 60.4% (19.8–80.4%) 5
RR: Rate Ratio, AFE: attributable fraction among those exposed, N: number of
studies the estimates are based on.
doi:10.1371/journal.pone.0027130.t003
Figure 1. Rate ratio of prostate cancer for first-degree family
history, i.e. affected father or brother relative to no first-
degree family history. Estimates from the case-control studies are
presented at the top. They are separated from the estimates from the
cohort-based studies with a line break.
doi:10.1371/journal.pone.0027130.g001
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and Australia. The identified studies differed regarding the study
design, the analysis, the way family history was ascertained, the
investigated type of clustering, and the reference category that they
used. 25 case-control studies and 8 cohort-based studies with non-
overlapping populations from 8 countries and 4 continents met the
inclusion criteria and reported data on the considered types of
clustering. According to our estimates, almost 60% of the prostate
cancer incidence among men with first-degree family history is
attributable to this risk factor.
The sensitivity analysis showed that the individual study results
had a small influence on the pooled estimates of the rate ratio for
first-degree family history, affected brother(s), and affected father.
The results for affected second-degree relatives and to 2 or more
affected first-degree family members, which are based on a small
number of studies, are more sensitive to changes in the sample of
studies used in the analysis and, therefore, should be treated with
caution. The meta-regression and the similarity between the
combined estimates based only on the cumulative-sampling case-
control studies and only on the density-sampling case-control
studies suggested that using the odds ratios from the cumulative-
sampling case-control studies as estimates of the rate ratios did not
substantially bias our estimates.
We did not attempt to identify unpublished studies. However,
neither the visual examination nor the statistical procedures
suggested that publication bias could have an important effect on
the estimates. With the exception of the study by Glover et al. [58],
the studies included in the analysis were conducted in developed
countries, most of them in the USA. Our analysis did not suggest
Figure 2. Rate ratio of prostate cancer for a history of prostate
cancer in father. Estimates from the case-control studies are
presented at the top. They are separated from the estimates from the
cohort studies with a line break.
doi:10.1371/journal.pone.0027130.g002
Figure 3. Rate ratio of prostate cancer for a history of prostate
cancer in brother(s). Estimates from the case-control studies are
presented at the top. They are separated from the estimates from the
cohort studies with a line break.
doi:10.1371/journal.pone.0027130.g003
Figure 4. Funnel plot for affected first-degree relatives. The
study of Suzuki et al., which may be subject to publication bias, is
indicated with a square.
doi:10.1371/journal.pone.0027130.g004
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USA and other countries exists. However, generalizing the results
to males not living in developed countries may be inappropriate.
The population in most of the considered studies was Caucasian.
However, the meta-regression showed that the effect of ethnicity
on the rate ratio for first-degree family history was small and not
significant. This finding suggests that the strength of the
association between family history and prostate cancer for
Caucasian males is similar as in other populations.
The amount of evidence on the relationship between family
history and prostate cancer that was available in our study was
much larger, than in the previous meta-analysis. Since 2003, the
strength of the associations has been investigated in a number of
new populations and a more recent data has been reported from
the Swedish cancer register and the Utah population database.
This allowed using stringent inclusion criteria and at the same time
retaining a substantial number of studies. In contrast to the
previous works, several measures were taken in order to improve
the quality of the analysis. To avoid a possible bias caused by
confounders the studies among specific populations such as
smokers [10] were excluded. As referring to prostate examination
may occur more frequently among men with prostate cancer
family history, the cross-sectional data gathered among males
referred to examination by a doctor [11,12,14] was not used.
Homogeneity of the studies was assured by including only the
studies in which family history was defined and corresponding to
one of the investigated types of clustering. Finally, as pooling of the
studies required the assumption of independence, overlaps in study
populations were avoided.
The results confirm the conclusions made in the previous meta-
analyses [3–5] and support the American Cancer Society
guidelines. We observed more than a 2-fold increase in the
incidence rate of the disease for all of the investigated types of
familial clustering, meaning that over 50% of prostate cancer cases
among men with a certain type of family history are attributable to
familial clustering of the disease. Having a brother with prostate
cancer appears to be associated with a larger increase in the
incidence rate than being a son of a father with prostate cancer.
The incidence rate increases with an increasing number of affected
family members. Family history appears to increase the incidence
rate of prostate cancer for males younger than 65 more, than for
males aged 65 and older, which suggests the relative importance of
genetic factors and/or shared environment and/or food factors in
an early onset of prostate cancer. In line with our conclusions, the
American Cancer Society (ACS) recommends that men at average
risk should be offered testing beginning at age 50, and that men at
increased risk for prostate cancer, such as those with a history of
the disease in a father or brother at a young age, should begin
testing with both the prostate specific antigen blood test and the
digital rectal examination at age 45, or even younger if they have
multiple relatives with the disease.
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